Immunovia to Host a Third Webinar in the Series on IMMray™ PanCan-d: Verification Study and Clinical Use

Immunovia to Host a Third Webinar in the Series on IMMray™ PanCan-d: Verification Study and Clinical Use

PR Newswire

LUND, Sweden, Dec. 11, 2020

LUND, Sweden, Dec. 11, 2020 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia"), a near-commercial stage diagnostics company developing ground-breaking antibody-based multiplex microarray technology platform called IMMray™ for the early detection of cancer, today announced that the company will be hosting the third webinar in the series on IMMray™ PanCan-d, Immunovia's test for early detection of pancreatic cancer. This third webinar will cover IMMray™

PanCan-d verification study results and its clinical use including feedback from experts in pancreatic cancer and pancreatic diseases.

Event Details: Webinar No. 3: Immunovia's IMMray™ PanCan-d Webinar Series Verification Study and Clinical Use

Date and Time: December 17, 2020 at 15:00 CET

Moderator for the Webinar is CEO Patrik Dahlen

Presenters: Thomas King, MD, PhD, Linda Mellby, PhD, VP R&D; and Laura Chirica, CCO, PhD, Immunovia

Immediately after the webinar, the Immunovia team will host a live Q&A session.

Webinar login and access details will be released on Monday Dec 14, 2020.

About the presenters:

Dr. Thomas King, Medical Director, Immunovia

Dr. King is a board-certified MD Pathologist with a PhD in Molecular Biology also from Washington University in St. Louis. Dr. King also has extensive experience as a Laboratory Director in hospital, academic and corporate settings in New England. He has deep expertise in laboratory administration and automation, surgical pathology, and molecular pathology and is currently an Adjunct Associate Professor in the School of Health Professions, Rutgers University.

Dr. Linda Mellby, VP Research & Development, Immunovia

Dr. Mellby received her PhD in Immunotechnology from the Department of Immunotechnology within CREATE Health Translational Cancer Center, Lund University, and a MSc in Chemistry Engineering. Mellby has 15+ years of experience in recombinant antibody microarray technology, Immunovia's IMMray platform. Additionally, she has deep knowledge on platform features, technology development, as well as, clinical applications within oncoproteomics and autoimmunity.

Dr. Laura Chirica, Chief Commercial Officer, Immunovia

Dr. Chirica received her PhD in Biochemistry from Umeå University, Sweden, and a MSc in Biochemistry and a BSc in Biotechnology. With more than 15+ years of experiences in leading commercial positions within the life science and diagnostics industry, Dr. Chirica contributes with extensive experience in business, organization and strategic development, sales, strategic and tactical marketing, product management and product support. She has a track record of leading and restructuring international sales and marketing organizations, driving business development, champion integration of acquired companies as well as developing branding and market communication platforms.

For more information, please contact:

Patrik Dahlen, CEO Immunovia

Email: patrik.dahlen@immunovia.com

Tel: +46 73 376 76 64

About Immunovia

Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia's proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique "disease biomarker signature".

The company was founded in 2007, based on cancer studies and groundbreaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.

The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world's largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is currently in the final validation phase. The company aims for a sales start at the end of Q1 2021 with subsequent commercial testing in Q2.

When validated, IMMray™ PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome.

Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and Lund, Sweden will provide laboratory testing services in two accredited reference laboratories.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/immunovia-to-host-a-third-webinar-in-the-series-on-immray--pancan-d--verification-study-and-clinical,c3253308

The following files are available for download:

https://mb.cision.com/Main/13121/3253308/1347348.pdf

Press release (PDF)

Voltar noticias em Inglês